Jazz Pharmaceuticals (JAZZ) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$218.42
-1.8% on the day
+58.1% over 12 months
52-week range $131.16 – $261.62
Share price and insider trades
JAZZ closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$69.8M
Insiders buying0
Insiders selling11
Jazz Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 11 sold $69.8M of JAZZ stock on the open market.
Get emailed when insiders cluster-buy stocks like JAZZ
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
JAZZ insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $1.9M | 2 |
| Q3 2026 | — | 0 | $24.4M | 11 |
| Q2 2026 | — | 0 | $7.4M | 11 |
| Q1 2026 | — | 0 | $14.2M | 19 |
| Q4 2025 | — | 0 | $22.7M | 18 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Jazz Pharmaceuticals plc insiders reported open-market purchases totaling $0, while 11 insiders reported sales totaling $69.8M. 27 of 61 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 7SEC | Renee D GalaCEO, President | Sell Plan | 2,000141,394 held (−1%) | $236.40 | $473K | -7.6% | — |
| Oct 5SEC | Bruce C CozaddDirector | Sell Plan | 6,000345,875 held (−2%) | $230.33 | $1.4M | -5.2% | — |
| Sep 14SEC | Neena M PatilGeneral Counsel | Sell Plan | 1,20047,671 held (−2%) | $240.94 | $289K | -9.3% | — |
| Sep 10SEC | Renee D GalaCEO, President | Sell Plan | 2,000143,394 held (−1%) | $243.03 | $486K | -10.1% | — |
| Sep 2SEC | Bruce C CozaddDirector | Sell Plan | 6,000351,875 held (−2%) | $250.13 | $1.5M | -12.7% | — |
| Aug 31SEC | Robert IannoneEvp, Global Head Of R&D & Cmo | Sell Plan | 19,63975,245 held (−21%) | $250.60 | $4.9M | -12.8% | — |
| Aug 31SEC | Robert IannoneEvp, Global Head Of R&D & Cmo | Sell Plan | 18,11394,884 held (−16%) | $250.02 | $4.5M | -12.6% | — |
| Aug 31SEC | Robert IannoneEvp, Global Head Of R&D & Cmo | Sell Plan | 18,187124,420 held (−13%) | $247.86 | $4.5M | -11.9% | — |
| Aug 31SEC | Robert IannoneEvp, Global Head Of R&D & Cmo | Sell Plan | 11,423112,997 held (−9%) | $248.67 | $2.8M | -12.2% | — |
| Aug 31SEC | Robert IannoneEvp, Global Head Of R&D & Cmo | Sell Plan | 9,25965,986 held (−12%) | $251.95 | $2.3M | -13.3% | — |
| Aug 31SEC | Robert IannoneEvp, Global Head Of R&D & Cmo | Sell Plan | 30065,686 held (−0%) | $252.76 | $76K | -13.6% | — |
| Aug 5SEC | Bruce C CozaddDirector | Sell Plan | 6,000360,682 held (−2%) | $252.98 | $1.5M | -13.7% | — |
| Jul 6SEC | Bruce C CozaddDirector | Sell Plan | 6,000366,682 held (−2%) | $240.47 | $1.4M | -9.2% | — |
| Jun 17SEC | Mark Douglas SmithDirector | Sell Plan | 1,1579,680 held (−11%) | $230.55 | $267K | -5.3% | — |
| Jun 12SEC | Neena M PatilGeneral Counsel | Sell Plan | 1,20051,549 held (−2%) | $231.83 | $278K | -5.8% | — |
| Jun 3SEC | Bruce C CozaddDirector | Sell Plan | 6,000372,682 held (−2%) | $235.12 | $1.4M | -7.1% | — |
| Jun 1SEC | Samantha PearceEvp, Chief Commercial Officer | Sell | 6,90750,272 held (−12%) | $235.41 | $1.6M | -7.2% | — |
| Jun 1SEC | Neena M PatilGeneral Counsel | Sell Plan | 1,19252,626 held (−2%) | $236.97 | $282K | -7.8% | — |
| May 27SEC | Rick E WinninghamDirector | Sell | 2,7419,567 held (−22%) | $241.57 | $662K | -9.6% | — |
| May 27SEC | Heather Ann McsharryDirector | Sell | 2,00018,449 held (−10%) | $241.00 | $482K | -9.4% | — |
| May 5SEC | Bruce C CozaddDirector | Sell Plan | 6,000378,682 held (−2%) | $203.33 | $1.2M | +7.4% | — |
| Apr 3SEC | Bruce C CozaddDirector | Sell Plan | 3,684386,998 held (−1%) | $190.22 | $701K | +14.8% | — |
| Apr 3SEC | Bruce C CozaddDirector | Sell Plan | 2,292384,706 held (−1%) | $190.94 | $438K | +14.4% | — |
| Apr 3SEC | Bruce C CozaddDirector | Sell Plan | 24384,682 held (−0%) | $191.74 | $5K | +13.9% | — |
| Mar 9SEC | Patricia CarrSvp, Chief Accounting Officer | Sell | 1,2876,512 held (−17%) | $182.94 | $235K | +19.4% | — |
| Mar 4SEC | Bruce C CozaddDirector | Sell Plan | 3,159408,637 held (−1%) | $186.09 | $588K | +17.4% | — |
| Mar 4SEC | Bruce C CozaddDirector | Sell Plan | 2,608406,029 held (−1%) | $186.73 | $487K | +17.0% | — |
| Mar 4SEC | Bruce C CozaddDirector | Sell Plan | 233405,796 held (−0%) | $187.84 | $44K | +16.3% | — |
| Mar 2SEC | Neena M PatilGeneral Counsel | Sell | 16,60256,862 held (−23%) | $192.53 | $3.2M | +13.4% | — |
| Mar 2SEC | Neena M PatilGeneral Counsel | Sell | 15,55568,391 held (−19%) | $190.28 | $3.0M | +14.8% | — |
| Mar 2SEC | Neena M PatilGeneral Counsel | Sell | 11,52966,941 held (−15%) | $191.65 | $2.2M | +14.0% | — |
| Mar 2SEC | Mary Elizabeth HendersonSvp, Technical Operations | Sell | 5,34328,728 held (−16%) | $194.49 | $1.0M | +12.3% | — |
| Mar 2SEC | Neena M PatilGeneral Counsel | Sell | 3,52363,418 held (−5%) | $193.58 | $682K | +12.8% | — |
| Mar 2SEC | Norbert G RiedelDirector | Sell | 3,4157,024 held (−33%) | $192.00 | $656K | +13.8% | — |
| Mar 2SEC | Neena M PatilGeneral Counsel | Sell | 2,91668,391 held (−4%) | $189.81 | $553K | +15.1% | — |
| Mar 2SEC | Neena M PatilGeneral Counsel | Sell | 1,78460,024 held (−3%) | $191.88 | $342K | +13.8% | — |
| Mar 2SEC | Patricia CarrSvp, Chief Accounting Officer | Sell | 1,25310,352 held (−11%) | $194.11 | $243K | +12.5% | — |
| Mar 2SEC | Patricia CarrSvp, Chief Accounting Officer | Sell | 1,1179,235 held (−11%) | $190.91 | $213K | +14.4% | — |
| Mar 2SEC | Neena M PatilGeneral Counsel | Sell | 1,06162,357 held (−2%) | $190.00 | $202K | +15.0% | — |
| Mar 2SEC | Neena M PatilGeneral Counsel | Sell | 1,00959,015 held (−2%) | $192.79 | $195K | +13.3% | — |
| Mar 2SEC | Neena M PatilGeneral Counsel | Sell | 87556,862 held (−2%) | $192.07 | $168K | +13.7% | — |
| Mar 2SEC | Neena M PatilGeneral Counsel | Sell | 54961,808 held (−1%) | $190.80 | $105K | +14.5% | — |
| Mar 2SEC | Neena M PatilGeneral Counsel | Sell | 19758,818 held (−0%) | $193.60 | $38K | +12.8% | — |
| Dec 11SEC | Mary Elizabeth HendersonSvp, Technical Operations | Sell | 2,23819,508 held (−10%) | $169.51 | $379K | +28.9% | — |
| Dec 9SEC | Patricia CarrSvp, Chief Accounting Officer | Sell | 4,5007,012 held (−39%) | $171.20 | $770K | +27.6% | — |
| Dec 9SEC | Patricia CarrSvp, Chief Accounting Officer | Sell | 1607,012 held (−2%) | $171.11 | $27K | +27.6% | — |
| Dec 1SEC | Bruce C CozaddDirector | Sell | 38,126393,332 held (−9%) | $177.27 | $6.8M | +23.2% | — |
| Dec 1SEC | Bruce C CozaddDirector | Sell | 30,487440,345 held (−6%) | $178.06 | $5.4M | +22.7% | — |
| Dec 1SEC | Bruce C CozaddDirector | Sell | 8,380431,965 held (−2%) | $179.23 | $1.5M | +21.9% | — |
| Dec 1SEC | Bruce C CozaddDirector | Sell | 507431,458 held (−0%) | $179.79 | $91K | +21.5% | — |
| Nov 24SEC | Heather Ann McsharryDirector | Sell | 3,41520,449 held (−14%) | $177.78 | $607K | +22.9% | — |
| Nov 20SEC | Bruce C CozaddDirector | Sell | 8,382397,060 held (−2%) | $180.88 | $1.5M | +20.8% | — |
| Nov 20SEC | Bruce C CozaddDirector | Sell | 5,517391,543 held (−1%) | $181.81 | $1.0M | +20.1% | — |
| Nov 20SEC | Rick E WinninghamDirector | Sell | 5,5008,893 held (−38%) | $180.86 | $995K | +20.8% | — |
| Nov 20SEC | Patricia CarrSvp, Chief Accounting Officer | Sell | 5,2507,012 held (−43%) | $182.07 | $956K | +20.0% | — |
| Nov 20SEC | Bruce C CozaddDirector | Sell | 3,384405,442 held (−1%) | $180.09 | $609K | +21.3% | — |
| Nov 20SEC | Bruce C CozaddDirector | Sell | 717390,826 held (−0%) | $182.60 | $131K | +19.6% | — |
| Nov 20SEC | Patricia CarrSvp, Chief Accounting Officer | Sell | 697,012 held (−1%) | $181.66 | $13K | +20.2% | — |
| Nov 19SEC | Robert IannoneEvp, Global Head Of R&D & Cmo | Sell Plan | 7,15972,628 held (−9%) | $168.26 | $1.2M | +29.8% | — |
| Oct 3SEC | Bruce C CozaddDirector | Sell Plan | 3,500408,826 held (−1%) | $140.00 | $490K | +56.0% | — |
| Oct 3SEC | Bruce C CozaddDirector | Sell Plan | 2,000412,326 held (−0%) | $131.78 | $264K | +65.7% | — |
Insiders at Jazz Pharmaceuticals plc
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Bruce C CozaddDirector | — | $28.5M | Oct 5, 2026 | — |
| Robert IannoneEvp, Global Head Of R&D & Cmo | — | $20.4M | Aug 31, 2026 | — |
| Neena M PatilGeneral Counsel | — | $11.5M | Sep 14, 2026 | — |
| Patricia CarrSvp, Chief Accounting Officer | — | $2.5M | Mar 9, 2026 | — |
| Rick E WinninghamDirector | — | $1.7M | May 27, 2026 | — |
| Samantha PearceEvp, Chief Commercial Officer | — | $1.6M | Jun 1, 2026 | — |
| Mary Elizabeth HendersonSvp, Technical Operations | — | $1.4M | Mar 2, 2026 | — |
| Heather Ann McsharryDirector | — | $1.1M | May 27, 2026 | — |
| Renee D GalaCEO, President | — | $959K | Oct 7, 2026 | — |
| Norbert G RiedelDirector | — | $656K | Mar 2, 2026 | — |
| Mark Douglas SmithDirector | — | $267K | Jun 17, 2026 | — |
JAZZ stock: common questions
Are Jazz Pharmaceuticals plc insiders buying JAZZ stock?
In the past 12 months, 0 insiders reported open-market purchases of JAZZ worth $0.
Are Jazz Pharmaceuticals plc insiders selling JAZZ stock?
11 insiders reported sales worth $69.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is JAZZ's 52-week range?
Over the past year JAZZ has traded between $131.16 and $261.62. It last closed at $218.42 on Oct 9, 2026.